Effects of Teriflunomide on B Cell Subsets in MuSK-Induced Experimental Autoimmune Myasthenia Gravis and Multiple Sclerosis

References

• Allman W, Qi H, Saini SS, Li J, Tuzun E, Christadoss P. 2012. CD4 costimulation is not required in a novel LPS-enhanced model of myasthenia gravis. J Neuroimmunol. 249(1–2):1–7.
   PubMed Web of Science ®Google Scholar
• Baggi F, Nicolle M, Vincent A, Matsuo H, Willcox N, Newsom-Davis J. 1993. Presentation of endogenous acetylcholine receptor epitope by an MHC class II-transfected human muscle cell line to a specific CD4+ T cell clone from a myasthenia gravis patient. J Neuroimmunol. 46:57–65.
   PubMed Web of Science ®Google Scholar
• Bruneau JM, Yea CM, Spinella-Jaegle S, Fudali C, Woodward K, Robson PA, Sautès C, Westwood R, Kuo EA, Williamson RA, et al. 1998. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J. 336:299–303.
   PubMed Web of Science ®Google Scholar
• Cetin H, Pathogenic Mechanisms VA. 2018. Clinical correlations in autoimmune myasthenic syndromes. Semin Neurol. 38:344–54.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Sun L, Xie Z, Fan X, Cao Q, Han J, Zhu J, Jin T. 2017. Diversity of immune cell types in multiple sclerosis and its animal model: pathological and therapeutic implications. J Neurosci Res. 95:1973–83.
   PubMed Web of Science ®Google Scholar
• Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, Young JM, Nakano G, Ransom JT. 1995. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther. 275:1043–49.
   PubMed Web of Science ®Google Scholar
• Comi G, Miller AE, Benamor M, Truffinet P, Poole EM, Freedman MS. 2019. Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: pooled analysis of clinical trials. Mult Scler. 1352458519851981. doi:https://doi.org/10.1177/1352458519851981
   Google Scholar
• Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, Marino M. 2018. Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 1412:82–89.
   PubMed Web of Science ®Google Scholar
• Fuentealba RA, Marasa J, Diamond MI, Piwnica-Worms D, Weihl CC. 2012. An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum Mol Genet. 21:664–80.
   PubMed Web of Science ®Google Scholar
• Gandoglia I, Ivaldi F, Laroni A, Benvenuto F, Solaro C, Mancardi G, Kerlero de Rosbo N, Uccelli A. 2017. Teriflunomide treatment reduces B cells in patients with MS. Neurol Neuroimmunol Neuroinflamm. 4:e403.
   PubMed Web of Science ®Google Scholar
• Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, Howard JF Jr, Scuderi F, Bartoccioni E, Evoli A, et al. 2015. Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurol Neuroimmunol Neuroinflamm. 2:e77.
   PubMed Web of Science ®Google Scholar
• Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, Veale DJ, Breedveld FC, Emery P, Tak PP. 2000. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. 43:1820–30.
   PubMed Web of Science ®Google Scholar
• Lebrun C, Bourg V, Bresch S, Cohen M, Rosenthal-Allieri MA, Desnuelle C, Ticchioni M. 2016. Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. J Neuroimmunol. 298:79–81.
   PubMed Web of Science ®Google Scholar
• Mandola AB, Levy J, Nahum A, Hadad N, Levy R, Rylova A, Simon AJ, Lev A, Somech R, Broides A. 2019. Neutrophil functions in immunodeficiency due to DOCK8 deficiency. Immunol Invest. 48:431–39.
   PubMed Web of Science ®Google Scholar
• Medina S, Sainz de la Maza S, Villarrubia N, Álvarez-Lafuente R, Costa-Frossard L, Arroyo R, Monreal E, Tejeda-Velarde A, Rodríguez-Martín E, Roldán E, et al. 2019. Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. Ann Clin Transl Neurol. 6:355–63.
   PubMed Web of Science ®Google Scholar
• Merrill JE, Hanak S, Pu SF, Liang J, Dang C, Iglesias-Bregna D, Harvey B, Zhu B, McMonagle-Strucko K. 2009. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol. 256:89–103.
   PubMed Web of Science ®Google Scholar
• Muto K, Matsui N, Unai Y, Sakai W, Haji S, Udaka K, Miki H, Furukawa T, Abe M, Kaji R. 2017. Memory B cell resurgence requires repeated rituximab in myasthenia gravis. Neuromuscul Disord. 27:918–22.
   PubMed Web of Science ®Google Scholar
• Rahmati M, Ghannadian SM, Kasiri N, Ahmadi L, Motedayyen H, Shaygannejad V, Pourazar A, Alsahebfosoul F, Ganjalikhani Hakemi M, Eskandari N. 2020. Modulation of Th17 proliferation and IL-17A gene expression by acetylated form of apigenin in patients with multiple sclerosis. Immunol Invest. 1–14. doi:https://doi.org/10.1080/08820139.2020.1726381
   Google Scholar
• Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, Tsujihata M, Vincent A, Eguchi K. 2005. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol. 57:289–93.
   PubMed Web of Science ®Google Scholar
• Si R, Zhao P, Yu Z, Qu Z, Sun W, Li T, Jiang Y. 2020. Increased non-switched memory B cells are associated with plasmablasts, serum IL-6 levels and renal functional impairments in IgAN patients. Immunol Invest. 49:178–90.
   PubMed Web of Science ®Google Scholar
• Solovjov DA, Pluskota E, Plow EF. 2005. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem. 280:1336–45.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, et al. 2018 Feb. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17(2):162–73. doi:https://doi.org/10.1016/S1474-4422(17)30470-2.
   PubMed Web of Science ®Google Scholar
• Trakas N, Zisimopoulou P, Tzartos SJ. 2011. Development of a highly sensitive diagnostic assay for muscle-specific tyrosine kinase (MuSK) autoantibodies in myasthenia gravis. J Neuroimmunol. 240–241:79–86.
   PubMed Web of Science ®Google Scholar
• Trapp BD, Nave KA. 2008. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 31:247–69.
   PubMed Web of Science ®Google Scholar
• Tuzun E, Berrih-Aknin S, Brenner T, Kusner LL, Le Panse R, Yang H, Tzartos S, Christadoss P. 2015. Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization. Exp Neurol. 270:11–17. doi:https://doi.org/10.1016/j.expneurol.2015.02.009
   PubMed Web of Science ®Google Scholar
• Tuzun E, Christadoss P. 2013. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev. 12:904–11.
   PubMed Web of Science ®Google Scholar
• Ulusoy C, Kim E, Tüzün E, Huda R, Yılmaz V, Poulas K, Trakas N, Skriapa L, Niarchos A, Strait RT, et al. 2014. Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice. Clin Immunol. 151:155–63.
   PubMed Web of Science ®Google Scholar
• Wu B, Goluszko E, Christadoss P. 2001 May. Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol. 15(8):1–26.
   Google Scholar
• Yilmaz V, Oflazer P, Aysal F, Durmus H, Poulas K, Yentur SP, Gulsen-Parman Y, Tzartos S, Marx A, Tuzun E, et al. 2015. Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK. PLoS One. 10:e0123546.
   PubMed Web of Science ®Google Scholar